942921-84-8

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-2-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE
• Synonyms: 1,2,3,4-TETRAHYDRO-2-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE
• CAS NO: 942921-84-8
• Molecular Formula: C16H24BNO2
• Molecular Weight: 273.18
• Mol File: 942921-84-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-2-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-2-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE(942921-84-8)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-2-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE(942921-84-8)

Safety Data

• Hazardous Substances Data: 942921-84-8(Hazardous Substances Data)

Usage

Chemical structure

A complex chemical compound with a bicyclic structure derived from isoquinoline.

Isoquinoline derivative

A heterocyclic compound with a bicyclic structure.

Tetramethyl-1,3,2-dioxaborolan-2-yl group

The presence of this boron-containing group suggests potential applications in organic synthesis and medicinal chemistry.

Methyl and tetrahydro groups

The presence of these groups indicates that the compound may possess unique physical and chemical properties.

Potential applications

The compound may have potential uses in various fields of research and industry, including drug development, material science, and other areas of chemical research.

Further studies

Further research on this compound may reveal its potential uses and applications in different fields.

Upstream product

• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

HETEROARYL SYK INHIBITORS

The invention relates to new substituted heteroarylsof formula (1) wherein A is selected from the group consisting of N and CH, D is selected from the group consisting of S and O, E is C, T is C, G is C, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.